| 汪 杰,李宏增,郭 俊,赵待弟,李 川.美金刚联合普拉克索治疗帕金森患者临床疗效及对CysC、Hcy水平影响[J].,2020,(13):2483-2487 |
| 美金刚联合普拉克索治疗帕金森患者临床疗效及对CysC、Hcy水平影响 |
| Effect of Memantine Combined with Pramipexole on the Level of CysC and Hcy in Patients with Parkinson's Disease |
| 投稿时间：2020-02-08 修订日期：2020-02-28 |
| DOI：10.13241/j.cnki.pmb.2020.13.017 |
| 中文关键词: 美金刚 普拉克索 帕金森 胱抑素C（CysC） 血同型半胱氨酸（Hcy） |
| 英文关键词: Memantine Praxo Parkinson CysC Hcy |
| 基金项目:陕西省2019年重点研发计划项目（2019SF-009） |
|
| 摘要点击次数: 807 |
| 全文下载次数: 556 |
| 中文摘要: |
| 摘要 目的：探究美金刚联合普拉克索在治疗帕金森患者中的临床疗效，并就治疗对患者胱抑素C（cystatin C，CysC）以及血同型半胱氨酸（homocysteine，Hcy）水平的影响。方法：选择2018年1月至2020年1月于我院接受治疗的98例帕金森患者，随机数字表法均分为两组（每组各49例），对照组单纯接受美金刚治疗，研究组在对照组基础上加用普拉克索进行治疗，对比两组治疗有效率，治疗前后CysC、Hcy水平，以及治疗前后简易智能精神状态检查量表（mini mental state examination，MMSE）以及帕金森病评定量表III（parkinson comprehensive rating scale，UPDRS III）评分，最后对两组患者治疗中不良反应发生率进行统计对比。结果：（1）研究组患者治疗有效率明显高于对照组患者（P<0.05）；（2）治疗前两组患者Cys C、Hcy水平对比差异不具有统计学意义（P>0.05），治疗后研究组患者CysC、Hcy水平低于对照组（P<0.05）；（3）治疗前两组患者MMSE及UPDRS III量表评分对比差异不具有统计学意义（P>0.05），治疗后研究组患者MMSE得分高于对照组，UPDRS III量表评分低于对照组（P<0.05）；（4）两组治疗不良反应诸如胃肠道反应、嗜睡、体位性低血压等对比无差异（P>0.05）。结论：美金刚联合普拉克索对帕金森具有较好的治疗效果，能够显著改善患者认知及运动功能，降低CysC、Hcy水平，同时治疗安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of memantine and pramipexole in the treatment of Parkinson's patients, and the effect of treatment on the levels of cystatin C (CysC) and blood homocysteine (Hcy) in patients. Methods: 98 patients with Parkinson's disease who were treated in our hospital from January 2018 to January 2020 were selected as the research subjects. They were divided into experimental group and control group according to the random number table method (49 patients in each group). Patients in the control group received memantine treatment alone. Patients in the experimental group were treated with pramipexole on the basis of patients in the control group. Comparing the treatment efficiency of the two groups of patients, CysC and Hcy levels before and after treatment, and simple intelligent mental state tests before and after treatment. Scores (MMSE) and Parkinson's Disease Rating Scale III (UPDRS III) scores. Finally, the statistical comparison of the incidence of adverse reactions in the treatment of the two groups of patients was performed. Results: (1) The comparison showed that the treatment efficiency of the experimental group was significantly higher than Patients in the control group (P<0.05). (2) The comparison showed that the differences in CysC and Hcy levels between the two groups of patients before treatment were not statistically significant (P>0.05). CysC and Hcy levels in the experimental group were lower than those in the control group after treatment (P<0.05). (3) The comparison showed that there was no significant difference in the MMSE and UPDRS III scale scores between the two groups of patients before treatment (P>0.05). Higher than the control group, the UPDRS III scale score was lower than the control group (P<0.05). (4) There was no significant difference in the incidence of adverse reactions such as gastrointestinal reactions, lethargy, orthostatic hypotension among the two groups (P>0.05). Conclusion: Memantine combined with Praxor has a better therapeutic effect on Parkinson's, which can significantly improve patients' cognitive and motor functions, reduce CysC and Hcy levels, and at the same time have higher safety in treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
